Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to assess the efficacy of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence who report using methamphetamine 29 or less days during the 30 days prior to the start of signing consent.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute on Drug Abuse (NIDA)
• Treatments: Bupropion; Methamphetamine

Criteria

Inclusion Criteria:

• Must have a DSM-IV diagnosis of methamphetamine dependence as determined by MINI

• Must have at least 1 amphetamine or methamphetamine positive urine specimen after the start of screening and before randomization or provide information to verify recent use if a positive urine sample can't be obtained

• Must report using methamphetamine for 29 days or less during the 30 day period prior signing consent using the timeline follow-back method

• Must be willing and able to comply with study procedures

• Must be able to verbalize and understand consent forms and provide written informed consent

• Must be seeking treatment for methamphetamine dependence

Exclusion Criteria:

• Please contact study site for more information